LKFT Lakefront Biotherapeutics NV IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1421876 · Reporting currency EUR
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | 2021Q22021-06-30 | 2020Q22020-06-30 | 2019Q22019-06-30 | 2018Q22018-06-30 | 2017Q22017-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 139.77M | 99.59M | 58.74M | 49.68M | 26.93M |
| R&D expense | 138.87M | 147.45M | 94.37M | 81.68M | 47.98M |
| SG&A expense | 46.44M | 37.28M | 13.71M | 8.50M | 6.33M |
| Operating income | -46.75M | -88.17M | -44.37M | -33.75M | -21.68M |
| Pretax income | -64.96M | -116.61M | -47.19M | -21.70M | -35.55M |
| Income tax | -630,000 | 373,000 | 61,000 | 75,000 | 92,000 |
| Net income | -64.33M | -115.04M | -47.25M | -21.77M | -35.64M |
| EPS (basic) | -0.98 | -1.77 | -0.86 | -0.42 | -0.71 |
| EPS (diluted) | -0.98 | -1.77 | -0.86 | -0.42 | -0.71 |
| Balance sheet | |||||
| Cash & equivalents | 2.64B | 2.38B | 1.15B | 1.07B | 1.26B |
| Short-term investments | 2.36B | 3.18B | — | — | — |
| Receivables | 88.13M | 31.35M | 42.07M | 19.11M | — |
| Inventory | — | — | — | 267,000 | — |
| Current assets | 5.13B | 5.62B | 1.21B | 1.11B | — |
| PP&E, netmay include right-of-use assets (IFRS) | 111.90M | 73.79M | 51.18M | 17.85M | — |
| Intangibles | 63.07M | 39.25M | 7.19M | 1.40M | — |
| Total assets | 5.43B | 5.85B | 1.36B | 1.20B | — |
| Current liabilities | 576.99M | 618.54M | 188.71M | 246.59M | — |
| Total liabilities | 2.77B | 3.08B | 214.48M | 318.69M | — |
| Shareholders' equity | 2.66B | 2.77B | 1.14B | 885.66M | 1.07B |
| Cash flow statement | |||||
| Operating cash flow | — | — | — | — | — |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.